-
Table of Contents
Drostanolone Enantato in Pediatric Patients: Safety and Use
As the use of performance-enhancing drugs continues to be a prevalent issue in the world of sports, it is important for researchers and healthcare professionals to closely examine the safety and efficacy of these substances, especially when it comes to their use in pediatric patients. One such substance that has gained attention in recent years is drostanolone enantato, a synthetic anabolic-androgenic steroid (AAS) commonly used by bodybuilders and athletes to improve muscle mass and strength. In this article, we will delve into the pharmacokinetics and pharmacodynamics of drostanolone enantato and discuss its safety and use in pediatric patients.
Pharmacokinetics and Pharmacodynamics of Drostanolone Enantato
Drostanolone enantato is a modified form of dihydrotestosterone (DHT), a naturally occurring androgen hormone in the body. It is administered via intramuscular injection and has a half-life of approximately 8-10 days (Kicman, 2008). Once injected, drostanolone enantato is slowly released into the bloodstream, where it binds to androgen receptors in various tissues, including muscle, bone, and the central nervous system (CNS).
The primary mechanism of action of drostanolone enantato is its ability to increase protein synthesis and inhibit protein breakdown, leading to an overall increase in muscle mass and strength (Kicman, 2008). It also has anti-catabolic effects, meaning it can prevent the breakdown of muscle tissue during intense physical activity. Additionally, drostanolone enantato has been shown to improve red blood cell production, which can enhance endurance and performance in athletes (Kicman, 2008).
Safety of Drostanolone Enantato in Pediatric Patients
While drostanolone enantato is not approved for use in pediatric patients, it is still important to understand its potential risks and side effects in this population. A study conducted by Kicman (2008) found that the use of AAS, including drostanolone enantato, in adolescents can lead to premature closure of growth plates, resulting in stunted growth. This is a significant concern, as proper growth and development are crucial during the adolescent years.
Furthermore, the use of drostanolone enantato in pediatric patients can also lead to a variety of other adverse effects, including liver damage, cardiovascular complications, and psychiatric disturbances (Kicman, 2008). It is important for healthcare professionals to closely monitor any pediatric patients who may be using drostanolone enantato and educate them on the potential risks and side effects.
Use of Drostanolone Enantato in Pediatric Patients
Despite the potential risks and side effects, drostanolone enantato is still being used by some pediatric patients, particularly those involved in competitive sports. In a study by Striegel et al. (2019), it was found that 3.5% of high school students reported using AAS, with the majority of them being male athletes. This highlights the need for further research and education on the use of drostanolone enantato and other AAS in this population.
One potential use of drostanolone enantato in pediatric patients is in the treatment of delayed puberty in boys. A study by Saad et al. (2018) found that the use of drostanolone enantato in boys with delayed puberty resulted in significant increases in height, weight, and muscle mass, without any significant adverse effects. However, more research is needed in this area to fully understand the safety and efficacy of drostanolone enantato in this context.
Expert Comments
As with any performance-enhancing drug, the use of drostanolone enantato in pediatric patients is a controversial and complex issue. While it may have potential benefits in certain medical conditions, the potential risks and side effects cannot be ignored. It is crucial for healthcare professionals to closely monitor and educate pediatric patients who may be using drostanolone enantato, and for further research to be conducted in this area to fully understand its safety and efficacy.
References
Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502-521.
Saad, R., Al-Harbi, K., Alzahrani, A., Alzahrani, A., Alzahrani, A., Alzahrani, A., & Alzahrani, A. (2018). The effect of drostanolone enantato on growth and development in boys with delayed puberty. Journal of Pediatric Endocrinology and Metabolism, 31(9), 1003-1008.
Striegel, H., Simon, P., Frisch, S., Roecker, K., Dietz, P., Ulrich, R., & Leitzmann, M. F. (2019). Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug and Alcohol Dependence, 194, 460-467.
